Jeannet M, Wyss M, Babel J F, Regamey A
Schweiz Med Wochenschr. 1975 Nov 22;105(47):1590-1.
Patients with acute leukemia (AML and ALL) who received multiple transfusions of whole blood, platelets or granulocytes, may develop anti-HL-A immunization in spite of chemotherapy. The frequency of HL-A alloimmunization was studied in 21 patients with AML and in 11 children with ALL. Multispecific HL-A antibodies were detected in 10 patients with AML and in 8 with ALL. The presence of these antibodies was associated with febrile transfusion reactions and with immediate destruction of platelets or granulocytes. Selection of HL-A compatible donors eliminated those reactions and the platelet counts could be maintained at levels sufficient to avoid the risk of hemorrhage. It seems therefore warranted to transfuse exclusively HL-A compatible platelets or leukocytes, as soon as anti-HL-A immunization has been detected.
接受多次全血、血小板或粒细胞输血的急性白血病（急性髓细胞白血病和急性淋巴细胞白血病）患者，即便接受了化疗，仍可能发生抗人类白细胞抗原（HL - A）免疫反应。对21例急性髓细胞白血病患者和11例急性淋巴细胞白血病儿童患者的HL - A同种免疫频率进行了研究。在10例急性髓细胞白血病患者和8例急性淋巴细胞白血病患者中检测到多特异性HL - A抗体。这些抗体的存在与发热性输血反应以及血小板或粒细胞的即刻破坏有关。选择HL - A相容的供体可消除这些反应，并且血小板计数可维持在足以避免出血风险的水平。因此，一旦检测到抗HL - A免疫反应，似乎有必要仅输注HL - A相容的血小板或白细胞。
